Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.

home / authors / reungwetwattana-t-nakagawa-k-cho-bc-et-al-cns-response-to-osimertinib-versus-standard-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in-patients-with-untreated-egfr-mutated-advanced-non-small-cell-lung-cancer-published-online-august-28-2018-j-clin-oncol-2018-jco2018783118-doi-101200-jco2018783118

Articles

Study Summary: Osimertinib Versus Standard EGFR-TKI Therapy in Patients With EGFR-Mutated Advanced NSCLC and Brain Metastases at Baseline

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777